[1]KULLAK-UBLICK GA, ANDRADE RJ, MERZ M, et al.Druginduced liver injury:Recent advances in diagnosis and risk assessment[J].Gut, 2017, 66 (6) :1154-1164.
|
[2]WANG Q, YANG F, MIAO Q, et al.The clinical phenotypes of autoimmune hepatitis:A comprehensive review[J].J Autoimmun, 2016, 66:98-107.
|
[3]LUCENA MI, KAPLOWITZ N, HALLAL H, et al.Recurrent druginduced liver injury (DILI) with different drugs in the Spanish Registry:The dilemma of the relationship to autoimmune hepatitis[J].J Hepatol, 2011, 55 (4) :820-827.
|
[4]WEILER-NORMANN C, SCHRAMM C.Drug induced liver injury and its relationship to autoimmune hepatitis[J].J Hepatol, 2011, 55 (4) :747-749.
|
[5]PARIENTE EA, HAMOUD A, GOLDFAIN D, et al.Hepatitis caused by clometacin (Duperan) .Retrospective study of 30 cases.A model of autoimmune drug-induced hepatitis?[J].Gastroenterol Clin Biol, 1989, 13 (10) :769-774.
|
[6]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Autoimmune hepatitis[J].J Hepatol, 2015, 63 (4) :971-1004.
|
[7]CZAJA AJ.Drug-induced autoimmune-like hepatitis[J].Dig Dis Sci, 2011, 56 (4) :958-976.
|
[8]PERDICES EV, MEDINA-CALIZ I, HERNANDO S, et al.Hepatotoxicity associated with statin use:Analysis of the cases included in the Spanish Hepatotoxicity Registry[J].Rev Esp Enferm Dig, 2014, 106 (4) :246-254.
|
[9]GUZMAN G, KALLWITZ ER, WOJEWODA C, et al.Liver injury with features mimicking autoimmune hepatitis following the use of Black Cohosh[J].Case Rep Med, 2009, 2009:918156.
|
[10]EFE C, PURNAK T, OZASLAN E, et al.Drug-induced autoimmune hepatitis caused by anti-tumor necrosis factor alpha agents[J].Hepatology, 2010, 52 (6) :2246-2247.
|
[11]RODRIGUES S, LOPES S, MAGRO F, et al.Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy:A single center report of 8 cases[J].World J Gastroenterol, 2015, 28, 21 (24) :7584-7588.
|
[12]TERZIROLI BERETTA-PICCOLI B, MIELI-VERGANI G, BERTOLI R, et al.Atovaquone/proguanil-induced autoimmune-like hepatitis[J].Hepatol Commun, 2017, 1 (4) :293-298.
|
[13] de BOER YS, KOSINSKI AS, URBAN TJ, et al.Features of autoimmune hepatitis in patients with drug-induced liver injury[J].Clin Gastroenterol Hepatol, 2017, 15 (1) :103-112, e102.
|
[14]CHALASANI N, BONKOVSKY HL, FONTANA R, et al.Features and outcomes of 899 patients with drug-induced liver injury:The DILIN prospective study[J].Gastroenterology, 2015, 148 (7) :1340-1352, e1347.
|
[15]ANDRADE RJ, LUCENA MI, FERNANDEZ MC, et al.Drug-induced liver injury:An analysis of 461 incidences submitted to the Spanish registry over a 10-year period[J].Gastroenterology, 2005, 129 (2) :512-521.
|
[16]DEVARBHAVI H, RAJ S, ARADYA VH, et al.Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis:Patient characteristics, causes, and outcome in36 cases[J].Hepatology, 2016, 63 (3) :993-999.
|
[17]LIWINSKI T, SCHRAMM C.Autoimmune hepatitis-update on clinical management in 2017[J].Clin Res Hepatol Gastroenterol, 2017, 41 (6) :617-625.
|
[18]ZHANG WC, ZHAO FR, CHEN J, et al.Meta-analysis:Diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen/liver pancreas in autoimmune hepatitis[J].PLo S One, 2014, 9 (3) :e92267.
|
[19]SONTHALIA N, RATHI PM, JAIN SS, et al.Natural history and treatment outcomes of severe autoimmune hepatitis[J].J Clin Gastroenterol, 2017, 51 (6) :548-556.
|
[20]BALITZER D, SHAFIZADEH N, PETERS MG, et al.Autoimmune hepatitis:review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria[J].Mod Pathol, 2017, 30 (5) :773-783.
|
[21]KLEINER DE.Histopathological challenges in suspected drug-induced liver injury[J].Liver Int, 2018, 38 (2) :198-209.
|
[22]SUZUKI A, BRUNT EM, KLEINER DE, et al.The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J].Hepatology, 2011, 54 (3) :931-939.
|
[23]DANAN G, TESCHKE R.Drug-induced liver injury:Why is the roussel uclaf causality assessment method (RUCAM) still used 25years after its launch?[J].Drug Saf, 2018.[Epub ahead of print].
|
[24]TESCHKE R, SCHULZE J, EICKHOFF A, et al.Drug induced liver injury:Can biomarkers assist RUCAM in causality assessment?[J].Int J Mol Sci, 2017, 18 (4) :e803.
|
[25]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.
|
[26]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Infectious Diseases, Chinese Medical Association.Consensus on the diagnosis and management of autoimmune hepatitis (2015) [J].J Clin Hepatol, 2016, 32 (1) :9-22. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会.自身免疫性肝炎诊断和治疗共识 (2015) [J].临床肝胆病杂志, 2016, 32 (1) :9-22.
|